Boston Omaha Co. (NYSE:BOC – Get Rating) Director Frank H. Kenan II sold 10,790 shares of Boston Omaha stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $25.59, for a total transaction of $276,116.10. Following the sale, the director now directly owns 170,876 shares in the company, valued at approximately $4,372,716.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Boston Omaha Stock Down 5.4 %
Shares of NYSE BOC opened at $24.71 on Friday. The firm has a market cap of $733.89 million, a price-to-earnings ratio of -20.09 and a beta of 0.53. The company has a quick ratio of 2.93, a current ratio of 2.93 and a debt-to-equity ratio of 0.06. Boston Omaha Co. has a 52-week low of $18.68 and a 52-week high of $44.50. The business’s 50 day moving average is $25.40 and its two-hundred day moving average is $24.09.
Boston Omaha (NYSE:BOC – Get Rating) last announced its earnings results on Friday, August 12th. The company reported ($0.39) earnings per share (EPS) for the quarter. The firm had revenue of $20.90 million during the quarter, compared to analysts’ expectations of $20.54 million. Boston Omaha had a negative net margin of 53.19% and a negative return on equity of 7.05%.
Wall Street Analyst Weigh In
Boston Omaha Company Profile
Boston Omaha Corporation, together with its subsidiaries, engages in the outdoor billboard advertising business in the southeast United States. It is also involved in the surety insurance and related brokerage, broadband, and investment businesses. The company provides high-speed internet service to approximately 7,000 subscribers in communities in southern Arizona; and 10,000 subscribers in Salt Lake City, Park City, Ogden, Provo, and surrounding communities.
- Get a free copy of the StockNews.com research report on Boston Omaha (BOC)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Boston Omaha Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Omaha and related companies with MarketBeat.com's FREE daily email newsletter.